TALNETANT

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H22N2O2
Molecular Weight	382.4544
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](NC(=O)C1=C2C=CC=CC2=NC(C3=CC=CC=C3)=C1O)C4=CC=CC=C4

InChI

InChIKey=BIAVGWDGIJKWRM-FQEVSTJZSA-N

InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)/t20-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://ncats.nih.gov/files/SB223412.pdf
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800009015 https://en.wikipedia.org/wiki/Talnetant

Talnetant (SB-223412) is a selective, orally active neurokinin 3 receptor antagonist and is under development for the potential treatment of several disorders, including irritable bowel syndrome, schizophrenia, chronic obstructive pulmonary disease, cough, overactive bladder and urinary incontinence. The most common adverse effects were headache, fatigue, and nausea.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Neurokinin 3 receptor 8 Target ID: CHEMBL4429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9190866	Antagonist 2849	1.0 nM [Ki]
Neurokinin 2 receptor 6 Target ID: CHEMBL2327 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9190866	Antagonist 2849	144.0 nM [Ki]
Neurokinin 1 receptor 35 Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9190866	Antagonist 2849	100.0 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Irritable bowel syndrome 61 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16044668	Primary	Phase II 1147	Unknown Approved Use Unknown
Schizophrenia 305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16044668 http://adisinsight.springer.com/drugs/800009015	Primary	Phase II 1147	Unknown Approved Use Unknown
Urinary incontinence 14 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16044668 http://adisinsight.springer.com/drugs/800009015	Primary	Basic research	Unknown Approved Use Unknown

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18755817/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		TALNETANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 2 times / day multiple, oral Studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00103727	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://clinicaltrials.gov/ct2/show/NCT00103727	Sources: https://clinicaltrials.gov/ct2/show/NCT00103727

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P0020AX	https://www.1pchem.com/search?query=1P0020AX
A2B Chem	AA92905	http://a2bchem.com/prod/AA92905
AA Blocks	AA001ZRH	http://aablocks.com/goods/Goods/detail?id=AA001ZRH
AbovChem LLC	HY-14552A	http://www.abovchem.com/pc/en/product_list.aspx?wd=HY-14552A
AK Scientific	4080AH	https://aksci.com/item_detail.php?cat=4080AH
Angene	AGN-PC-0O4XVX	http://www.angenechemical.com/productshow/AGN-PC-0O4XVX.html
ApexBio Technology	A3854	https://www.apexbt.com/catalogsearch/result/?q=A3854
AstaTech	56181	http://astatechinc.com/CPSResult.php?CRNO=56181
BLD Pharm	BD262311	http://www.bldpharm.com/search/Search.html?keyword=BD262311
BLD Pharm	BD630526	http://www.bldpharm.com/search/Search.html?keyword=BD630526
BOC Sciences	174636-32-9	http://www.bocsci.com/description.asp?cas=174636-32-9
Chem Scene	CS-1638	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1638
ChemShuttle	169552	https://www.chemshuttle.com/catalogsearch/result/?q=169552
eMolecules	266610510	https://orderbb.emolecules.com/search/#?query=266610510
eMolecules	301145200	https://orderbb.emolecules.com/search/#?query=301145200
eMolecules	49837486	https://orderbb.emolecules.com/search/#?query=49837486
eMolecules	50283866	https://orderbb.emolecules.com/search/#?query=50283866
eMolecules	70145128	https://orderbb.emolecules.com/search/#?query=70145128
Excenen	EX-A894	http://www.excenen.com/searchresultlist.php?id=EX-A894
KeyOrganics	AS-72166	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-72166
Lab Network	LN01311468	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01311468
mcule	MCULE-3991197012	https://mcule.com/MCULE-3991197012/
mcule	MCULE-7106959917	https://mcule.com/MCULE-7106959917/
mcule	MCULE-7135163856	https://mcule.com/MCULE-7135163856/
mcule	MCULE-8672750156	https://mcule.com/MCULE-8672750156/
MedChem Express	HY-14552	https://www.medchemexpress.com/search.html?q=HY-14552&ft=&fa=&fp=
MolPort	MolPort-006-170-148	https://www.molport.com/shop/molecule-link/MolPort-006-170-148
MolPort	MolPort-035-758-899	https://www.molport.com/shop/molecule-link/MolPort-035-758-899
MuseChem	I002280	https://www.musechem.com/product/I002280.html
Princeton BioMolecular Research	PBMR240802	http://www.princetonbio.com/order_online?common_id=PBMR240802
Tocris	4672	https://www.tocris.com/search.php?Type=QuickSearch&Value=4672
Wonderchem	WD02VGS	http://www.wonder-chem.com/search.html?text=WD02VGS

PubMed

Title	Date	PubMed
Testicular toxicity induced by a triple neurokinin receptor antagonist in male dogs.	2011-05	21185367
Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies.	2004-08-15	15265501
Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.	2001-02-16	11226387
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.	1997-06	9190866
2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.	1996-06-07	8691422

Patents

Sample Use Guides

In Vivo Use Guide

0.1 mg to 1000 mg as single doses; up to 800 mg twice daily on repeat doses.

Route of Administration: Oral

In Vitro Use Guide

SB223412 antagonized senktide-induced contraction of rabbit isolated iris sphincter muscle (KB = 1.6 nM), and inhibited NK-3 receptorinduced membrane depolarization in guinea-pig bronchial parasympathetic ganglia and substantia nigra pars compacta in guinea pig. SB223412 inhibited senktide-induced miosis in rabbits when given iv (ED50 = 0.44mg/kg) and by 53% when given orally (25 mg/kg, PO).

Name

Type

Language

Talnetant [WHO-DD]

Preferred Name

English

TALNETANT

Official Name

English

N-((S)-.ALPHA.-ETHYLBENZYL)-3-HYDROXY-2-PHENYLCINCHONINAMIDE

Systematic Name

English

talnetant [INN]

Common Name

English

(S)-3-HYDROXY-2-PHENYL-N-(1-PHENYLPROPYL)-4-QUINOLINECARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698